China’s landmark competency-based longevity medicine program integrates traditional Chinese medicine with AI, aiming to transform elder care and preventive health. China has initiated a pioneeri...
China introduces a pioneering curriculum integrating aging biology, AI, nutrition, and traditional Chinese medicine to shift from reactive treatment to proactive healthspan management. China launches ...
China’s new national program trains doctors in longevity medicine, combining geroscience, AI, and TCM to extend healthspan, setting a global precedent. China’s bold new initiative trains m...
A new study in Aging Cell uncovers a bidirectional feedback loop between intestinal aging and gut microbiome changes, accelerating systemic inflammation. A study in Aging Cell reveals how age-related ...
A 2024 Nature Aging study shows IGF1R inhibitors PPP and NVP-ADW742 extend healthspan by 8–12% but cause GI bleeding and cardiotoxicity, questioning their therapeutic potential. A 2024 mouse study r...
The 2025 longevity investment landscape shifts from narrow anti-aging to a full innovation stack, led by cellular reprogramming, brain longevity diagnostics, and platform infrastructure. Investors pou...
Recent research uncovers strong correlations between gut bacteria composition and physical function in seniors, suggesting microbiome-targeted interventions could combat frailty. Can the bacteria in y...
Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
Research reveals vitamin C’s role in inhibiting ACSL4, reducing iron-driven oxidative damage and senescence in cynomolgus monkeys, positioning it as a promising geroprotective target for human h...
A new multi-phase clinical trial on rapamycin aims to establish safe dosing for anti-aging, bridging the gap between off-label use and scientific validation in longevity medicine. Recent advancements ...
